Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18-14/KM10B).

Breast · 2022 · PMC9429798 · PMID 36029565

Europe PMC DOI

hedged sentence

0.0660

closest p · 1.3× alpha

0.0660

boldest claim

The sentences

showed a trendp = 0.066so close (0.05 < p ≤ 0.1)

Patients with liver metastasis showed a trend of shorter PFS (HR = 1.47, 95% CI 0.98–2.21. p = 0.066).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.